




KAHIMMUNE
THERAPEUTICS

Reexploring the Cancer Immunoepitome





EXECUTIVE SUMMARY

-  Company founded in **November 2025** (Gustave Roussy spin-off, Europe's leading cancer center)
-  Based on a **new paradigm** uncovering how the **"dark genome"** plays a pivotal role in immune regulation - particularly in the cancer immunopeptidome
-  **Out-licensing (End of Phase 1)** of next-generation **mRNA-based immuno-oncology** therapies
-  Initial focus on **colorectal, pancreatic and lung cancers** (>4.9M cases/year)
-  **Exclusive** license agreement transferring **IP assets** to the company
-  A **seasoned team** covering entrepreneurship, BD&L, CMC, and immuno-oncology




DESPITE IMPROVED CARE, CANCER BURDEN IS GROWING



- > The global incidence of cancer will increase from 20M to 33M new cases annually through 2045
- > Lung, colorectal, and pancreatic cancers remain among the deadliest
- > **Recurrence remains a major challenge**

New cancer treatments are needed to improve survival and quality of life



While 98% of the human genome does not encode proteins, its biological significance is **only beginning** to be understood.

Kahimmune Therapeutics' scientific founders have uncovered how this "dark genome" plays a pivotal role in immune regulation - particularly in the **cancer immunoepitidome***.

These discoveries open **new avenues** for immunotherapy development, positioning Kahimmune at the forefront of a transformative approach to cancer treatment.

Kahimmune is leveraging groundbreaking insights into the "dark genome" to develop next-generation immuno-oncology therapies



AN EXPERIENCED TEAM DRIVING BIOTECH INNOVATION



Philippe Villain-Guillot, PhD | CEO (co-founder)

20+ years experience in Biotech and Drug Discovery
Former CEO and co-founder of Nosopharm (antimicrobial drug discovery and development)
Raised €17m in private equity and non-dilutive funding, dealt industrial and academic partnerships



Rene Chemali, PhD | CSO (co-founder)

PhD in Cancer Sciences with a specialization in immunology from Université Paris-Saclay and Gustave Roussy
Gustave Roussy (UMR 1015), Institut Pasteur, Collectis

Strategic Advisors



Guillaume Sirgue, MSc (co-founder)

20+ years experience in the manufacturing of vaccines and biologics
Director Technical Excellence in a CDMO
End-to-end Vaccine Product Leader (commercial and development) at Sanofi



Serge Sagodira, PhD

20+ years experience in BD&L (Addex, Debiopharm, Ariceum)
Strong in and out-licensing experience, including oncology
Over 10 transactions concluded (licenses and strategic partnerships)

Scientific/Clinical Advisors




Sebastien Apcher, PhD (co-founder)

Researcher Inserm, Saint-Louis Research Institute, Gustave Roussy
40 peer-reviewed scientific articles, 6 patent applications
Cancer Prize of the French National Academy of Medicine (2017)



Antoine Hollebecque, MD

Senior Medical Oncologist at Gustave Roussy
Expert in gastrointestinal cancer
200+ peer-reviewed scientific articles



BioNTech/Roche (NCT04161755)

Recurrence-Free Survival (RFS) stratified by INT response
Nature 2025, DOI: 10.1038/s41586-024-08508-4

- 🚀 **mRNA-based individualized neoantigen therapies (INTs):**
- > Show very promising results when combined with ICIs*
 - > Could be positioned as **high-value synergistic companions** to other cancer treatments by driving **T cell-mediated antitumor activity** and thereby improving patient outcomes


⚠️ **Challenges of INTs preventing “off-the-shelf” model:**

- > Access to patient-specific tumor biopsies (1 biopsy, 1 INT)
- > Identification of ultra-personalized somatic mutations
- > Real-life immunogenicity of the predicted neoantigens

Kahimmune is investigating a new class of shared neoantigens to develop “off-the-shelf” synergistic companion neoantigen therapies (CNTs)


PTP: REVEALING NEOANTIGENS CONCEALED IN THE DEEP “DARK GENOME”

- > Pioneer Translation Products (PTPs): small peptides synthesized by a non-canonical translation mechanism before RNA splicing from coding and non-coding genome (“dark genome”, 98% of the genome)
- > Model proposed and investigated by Dr. Apcher (co-founder) for 15+ years*



Classical Model of MHC-I Presentation

Antigens originate from the degradation of mature RNA encoded-proteins




PTP-Augmented Model of MHC-I Presentation

Antigens originate from non-canonical translation of immature RNA

PTPs represent a vast reservoir of neoantigens for MHC class I presentation.

PTP-based Kahinomics™ platform uncovers the blind spots of the “dark genome”.



Through a distinctive immunopeptidomics strategy, Kahimmune aims to uncover exclusive Kahigens™ that drive synergy in combination therapies

Product Candidates	Foreseen Combination	Cancer Indication	Discovery	Preclinical	Phase 1
KAH-001	Anti-VEGF (later: PD-1/L1xVEGF)	Colorectal cancer			
	Anti-PD-1/L1 (later: PD-1/L1xVEGF)	Pancreas cancer			
KAH-002	Radiotherapy	Lung cancer			
KAH-003	Bispecific Antibodies (TCEs)	Solid tumors			

 today  by 5 years

Kahimmune will build a diversified pipeline of novel synergistic CNTs and will seek early-stage collaborations for combined development



Kahimmune Therapeutics aims to partner with Pharma and Biotech companies to:

 Advance its pipeline of **Companion Neoantigen Therapies (CNTs)** and explore **innovative synergistic combinations**

 Explore collaborative applications of its neoantigen discovery platform Kahinomics™ beyond CNTs, including **TCR-engineered T cells (TCRs)**, **T Cell Engagers (TCEs)**, and other next-generation immunotherapies

We welcome discussions with partners interested in co-development, technology evaluation, or strategic collaborations